Levomilnacipran
SNRI antidepressant drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Levomilnacipran?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Levomilnacipran (brand name Fetzima) is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults.[5] It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).[8][9]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Fetzima |
AHFS/Drugs.com | Monograph |
Routes of administration | By mouth (capsules) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 92%[5] |
Protein binding | 22%[6] |
Metabolism | Hepatic (primarily by CYP3A4)[7] |
Elimination half-life | 12 hours[7] |
Excretion | Kidney[7] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C15H22N2O |
Molar mass | 246.354 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close